Albuferon Filings to be Submitted in the Fall, Analysts Question Product

Human Genome Sciences plans to file for approval of its hepatic C treatment Albuferon worldwide next fall, but there is no certainty yet that physicians will adopt the long-acting interferon. The company released results from its second Phase III trial designed to demonstrate that Albuferon (albinterferon alfa-2b) is not inferior to Roche’s Pegasys (peginterferon alfa-2a). During a conference call held to discuss the trial results, an analyst noted that despite the biologic being shown not to be inferior to Pegasys, the numerical response rate data favored Roche’s product.
Drug Industry Daily